Abstract

BackgroundTNFi drug survival is one of the valid outcome measure in rheumatological diseases. TNFi drug survival is not evaluated adequetly in non-radiographic axial spondyloarthritis (nr-axSpA).ObjectivesObjective of this study was to...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0835 Comparison of long term anti-tnf survival in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis; data from turkbio registry
N Akkoc ... S.S Koca
Annals of the Rheumatic Diseases | VOL. 77
N Akkoc, et. al.N Akkoc ... S.S Koca
01 Jun 2018
AB0648 COMPARING SYMPTOMS, TREATMENT PATTERNS, AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS PATIENTS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN JAPAN
E Holdsworth ... T Hunter
-
E Holdsworth, et. al.E Holdsworth ... T Hunter
01 Jun 2020
SAT0412 Patients with Psoriatic Arthritis HAD Better TNFI Survival than Ankylosing Spondylitis: HÜR-BİO REAL Life Results
O Karadag ... S.A Bilgen
Annals of the Rheumatic Diseases | VOL. 73
O Karadag, et. al.O Karadag ... S.A Bilgen
01 Jun 2014
POS1111 TREATMENT WITH UPADACITINIB RESULTS IN THE INHIBITION OF A BROAD RANGE OF POTENTIALLY PATHOGENIC PATHWAYS IN NR-AXSPA AND BDMARD-IR AS PATIENTS: PROTEOMIC ANALYSIS FROM THE SELECT-AXIS 2 PHASE 3 STUDIES
B Ravishankar ... P Wung
Annals of the Rheumatic Diseases | VOL. 82
B Ravishankar, et. al.B Ravishankar ... P Wung
30 May 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers